Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
Authors:
- Lisa VermijLVLisa Vermij
- Jan J. JobsenJJJan J. Jobsen
- Mariel BrinkhuisMBMariel Brinkhuis
- Melanie E. PowellMPMelanie E. Powell
- Stephanie M. de BoerSBStephanie M. de Boer
- Pearly KhawPKPearly Khaw
- Linda R. MileshkinLMLinda R. Mileshkin
- Anthony FylesAFAnthony Fyles
- Alexandra LearyALAlexandra Leary
- Catherine GenestieCGCatherine Genestie
Preprint
Abstract
Background: Risk-assessment of endometrial cancer (EC) is based on clinicopathological factors and molecular subgroup. It is unclear whether adding hormone receptor expression, L1CAM expression or CTNNB1 status yields prognostic refinement. Methods: Paraffin-embedded tumour samples of women with high-risk EC (HR-EC) from the PORTEC-3 trial (n=424), and a Dutch prospective clinical cohort called MST (n=256), were used. All cases were molecularly classified. Expression of L1CAM, ER and PR were analysed by whole-slide immunohistochemistry and CTNNB1 mutations were assessed with a next-generation sequencing. Kaplan-Meier method, log-rank tests and Cox’s proportional hazard models were used for survival analysis. Results: In total, 649 HR-EC were included. No independent prognostic value of ER, PR, L1CAM and CTNNB1 was found, while age, stage, and adjuvant chemotherapy had an independent impact on risk of recurrence. Subgroup-analysis showed that only in NSMP HR-EC, ER-positivity was independently associated with a reduced risk of recurrence (HR 0.33, 95%CI 0.15-0.75). Conclusions: ER-positivity is a strong favourable prognostic factor in NSMP HR-EC and identifies a homogeneous subgroup of NSMP tumours. ER-positive NSMP EC may be regarded as a novel fifth molecular subgroup. Assessment of ER status in high-risk NSMP EC is feasible in clinical practice and could improve risk stratification and treatment.Keywords
All Related Versions
- Published version: British Journal of Cancer, 128 (7), 1360.
This publication has 45 references indexed in Scilit:
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- The genetic landscape of endometrial clear cell carcinomasThe Journal of Pathology, 2017
- Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancerCancer, 2017
- Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trialsEuropean Journal of Cancer, 2015
- L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial resultsEuropean Journal of Cancer, 2014
- Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trialEuropean Journal of Cancer, 2013
- The EMT signaling pathways in endometrial carcinomaClinical and Translational Oncology, 2012
- Adjuvant progestagens for endometrial cancerCochrane Database of Systematic Reviews, 2011
- Up‐regulation of L1CAM is linked to loss of hormone receptors and E‐cadherin in aggressive subtypes of endometrial carcinomasThe Journal of Pathology, 2009
- Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancerGynecologic Oncology, 2009